SARTORIUS (UNSP.ADS)/1/5 Net Assets
SARTORIUS (UNSP.ADS)/1/5 net assets. Based on the latest financial reports, SARTORIUS (UNSP.ADS)/1/5 (SRT0) has net assets worth €3.89 Billion EUR (≈ $4.55 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€9.87 Billion ≈ $11.54 Billion USD) and total liabilities (€5.98 Billion ≈ $6.99 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See debt-free asset ratio of SARTORIUS (UNSP.ADS)/1/5 to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €3.89 Billion |
| % of Total Assets | 39.41% |
| Annual Growth Rate | 13.3% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 18.88 |
Net Assets of SARTORIUS (UNSP.ADS)/1/5 (2022–2025)
Net assets of SARTORIUS (UNSP.ADS)/1/5 from 2022 to 2025. This chart illustrates how SARTORIUS (UNSP.ADS)/1/5's net assets have evolved over time, based on quarterly financial data. Also explore SARTORIUS (UNSP.ADS)/1/5 equity growth rate to track the company's year-over-year net asset growth rate.
Annual Net Assets for SARTORIUS (UNSP.ADS)/1/5 (2022–2025)
The table below shows the annual net assets of SARTORIUS (UNSP.ADS)/1/5 from 2022 to 2025. For live market cap and overall valuation, see market value of SARTORIUS (UNSP.ADS)/1/5.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €3.87 Billion ≈ $4.52 Billion |
-0.78% |
| 2024-12-31 | €3.90 Billion ≈ $4.56 Billion |
+41.33% |
| 2023-12-31 | €2.76 Billion ≈ $3.22 Billion |
+3.73% |
| 2022-12-31 | €2.66 Billion ≈ $3.11 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to SARTORIUS (UNSP.ADS)/1/5's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 0.0% over the analyzed period, potentially due to dividend distributions or operating losses.
SARTORIUS (UNSP.ADS)/1/5 Net Assets Breakdown (December 2025)
SARTORIUS (UNSP.ADS)/1/5 net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €2.71 Billion | 100.00% |
| Total Equity | €2.71 Billion | 100.00% |
SARTORIUS (UNSP.ADS)/1/5 Competitors by Market Cap
The table below lists competitors of SARTORIUS (UNSP.ADS)/1/5 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GRAB HOLDINGS LTD CL.A
F:A6I
|
$11.40 Billion |
|
Erie Indemnity Company
NASDAQ:ERIE
|
$11.40 Billion |
|
Wiwynn Corp
TW:6669
|
$11.42 Billion |
|
Guidewire Software Inc
NYSE:GWRE
|
$11.42 Billion |
|
MILLICOM INTL CELL. DL15
F:M4M1
|
$11.39 Billion |
|
Metso Oyj
HE:METSO
|
$11.39 Billion |
|
H WORLD GROUP DL-00001
F:CL4
|
$11.38 Billion |
|
Guangdong Hec Technology Holding Co Ltd Class A
SHG:600673
|
$11.37 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SARTORIUS (UNSP.ADS)/1/5's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,764,800,000 to 2,706,800,000, a change of -58,000,000 (-2.1%).
- Net income of 154,900,000 contributed positively to equity growth.
- Dividend payments of 50,800,000 reduced retained earnings.
- Other factors decreased equity by 162,100,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €154.90 Million | +5.72% |
| Dividends Paid | €50.80 Million | -1.88% |
| Other Changes | €-162.10 Million | -5.99% |
| Total Change | €- | -2.10% |
Book Value vs Market Value Analysis
This analysis compares SARTORIUS (UNSP.ADS)/1/5's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.43x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.93x to 1.43x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | €29.08 | €56.00 | x |
| 2023-12-31 | €30.22 | €56.00 | x |
| 2024-12-31 | €40.05 | €56.00 | x |
| 2025-12-31 | €39.20 | €56.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SARTORIUS (UNSP.ADS)/1/5 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.72%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.38%
- • Asset Turnover: 0.36x
- • Equity Multiplier: 3.59x
- Recent ROE (5.72%) is below the historical average (13.20%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 34.08% | 16.24% | 0.60x | 3.51x | €479.12 Million |
| 2023 | 9.94% | 6.05% | 0.35x | 4.71x | €-1.18 Million |
| 2024 | 3.04% | 2.48% | 0.33x | 3.65x | €-192.48 Million |
| 2025 | 5.72% | 4.38% | 0.36x | 3.59x | €-115.78 Million |
Industry Comparison
This section compares SARTORIUS (UNSP.ADS)/1/5's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $5,770,613,218
- Average return on equity (ROE) among peers: 4.65%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SARTORIUS (UNSP.ADS)/1/5 (SRT0) | €3.89 Billion | 34.08% | 1.54x | $11.40 Billion |
| SCHOTT Pharma AG & Co. KGaA (1SXP) | $692.18 Million | 21.94% | 0.78x | $2.39 Billion |
| RENAU.UNSP.ARD 1/5 EO-20 (56S0) | $2.51 Billion | 34.85% | 1.01x | $17.02 Billion |
| MEDIMI AB AK (79T) | $15.25 Million | -101.01% | 0.19x | $1.70 Million |
| TEVANO SYSTEMS HLDGS INC. (7RBA) | $-736.70K | 0.00% | 0.00x | $210.67K |
| STEVANATO GROUP SPA O.N. (87N) | $841.66 Million | 15.96% | 0.69x | $1.05 Billion |
| Carl Zeiss Meditec AG (AFX) | $2.17 Billion | 13.36% | 0.40x | $2.23 Billion |
| CARL ZEISS MEDITEC ADR 1 (AFXA) | $2.17 Billion | 13.36% | 0.40x | $2.14 Billion |
| Bio-gate AG (BIG1) | $3.77 Million | -14.43% | 0.38x | $7.12 Million |
| COLOPLAST SP.ADR 1/10 DK1 (CBH) | $8.29 Billion | 56.75% | 3.52x | $12.73 Billion |
| ESSILORLUXOTTICA 1/2/O.N. (ESLC) | $41.00 Billion | 5.75% | 0.57x | $67.43 Billion |
About SARTORIUS (UNSP.ADS)/1/5
Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers analytical solutions, such as biolayer interferometry systems, high-throughput screening by cytometry systems, process analytical technology and data analytics, cell selection and retrieval, live-cell imaging and analysis systems, and surface plasmon resonance systems; cell cult… Read more